Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482809 | 0.89 | CUL4A (0.49) | CUL4AALDH1A1TP53RXFP1CCR2 | |
| SCHEMBL4498718 | 0.88 | CUL4A (0.51) | CUL4AALDH1A1TP53RXFP1CASP1 | |
| Potassium Ion SCHEMBL4511656 | 0.86 | CUL4A (0.50) | CUL4AALDH1A1TP53RXFP1CCR2 | |
| SCHEMBL4499121 | 0.85 | CUL4A (0.49) | CUL4AALDH1A1TP53RXFP1KMO | |
| SCHEMBL4511855 | 0.84 | CUL4A (0.48) | CUL4AALDH1A1TP53RXFP1CASP1 | |
| SCHEMBL4499374 | 0.84 | CUL4A (0.48) | CUL4AALDH1A1RXFP1TSHRMAPT | |
| SCHEMBL4488936 | 0.83 | MAPT (0.50) | ALDH1A1TP53RXFP1TSHRSMN1; SMN2 | |
| SCHEMBL4485871 | 0.83 | CCR2 (0.38) | CUL4AALDH1A1RXFP1CCR2SMN1; SMN2 | |
| SCHEMBL4495523 | 0.83 | TNKS (0.39) | CUL4AALDH1A1TP53RXFP1CCR2 | |
| SCHEMBL5102590 | 0.83 | CUL4A (0.47) | CUL4AALDH1A1TP53RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2005121138-A2 | HETEROTRICYCLIC COMPOUNDS FOR USE AS HCV INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | CUL4A 56/4885ALDH1A1 874/4885TP53 1925/4885 |
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | CUL4A 56/4885ALDH1A1 874/4885TP53 1925/4885 |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | HAVCR2, PYGL, HCCS | CUL4A 99/4885ALDH1A1 2575/4885TP53 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.